Seizure

Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc., ("Kriya") a biopharmaceutical company developing gene therapies for common diseases affecting millions of people around the world, today provided an update on its pipeline of gene therapies for prevalent conditions including geographic atrophy, thyroid eye disease, diabetes, NASH, trigeminal neuralgia and epilepsy. Kriya is advancing the first of its gene therapy product candidates into the clinic in 2024 and expects up to five programs in the clinic by the end of 2025.

Key Points: 
  • Kriya’s pipeline includes gene therapies across three major therapeutic areas: ophthalmology, metabolic disease and neurology.
  • Its programs share the following features: direct-to-tissue delivery, validated biology, de-risked clinical and regulatory paths and large commercial markets.
  • Dr. Ramaswamy will share further information on Kriya’s portfolio during his presentation at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9th at 9:00 AM PT in San Francisco, California.
  • A significant proportion of patients suffer from refractory epilepsy, many of whom are candidates for invasive neurosurgery.

Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio

Retrieved on: 
Monday, January 8, 2024

BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on its portfolio and planned key milestones in 2024:

Key Points: 
  • Praxis made strong progress in developing PRAX-628 for focal epilepsy, which affects over 1 million Americans.
  • Initial data from PRAX-628 show it has a good tolerability profile, a potentially wide therapeutic index and reaching efficacious concentrations within 24 hours.
  • A preliminary analysis of the 15 mg cohort showed that this cohort exceeds the expectations in terms of drug activity.
  • In 2023, Praxis disclosed results from a Phase 1 dose escalation study of PRAX-628 in healthy volunteers:
    PRAX-628 was generally well-tolerated at all tested doses.

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders

Retrieved on: 
Monday, January 8, 2024

11,839,600 entitled “NEURODEVELOPMENTAL DISORDER THERAPY” from the United States Patent and Trademark Office (USPTO) for its patent application number 17/890,083.

Key Points: 
  • 11,839,600 entitled “NEURODEVELOPMENTAL DISORDER THERAPY” from the United States Patent and Trademark Office (USPTO) for its patent application number 17/890,083.
  • Anavex’s newest patent expands coverage of ANAVEX®2-73 (blarcamesine) therapy to ameliorate various conditions associated with loss-of-function mutations of the gene encoding methyl-CpG binding protein (MeCP2).
  • This newest patent is expected to remain in force at least until January 2037, not including any patent term extension.
  • The grant of this new patent to Anavex further demonstrates our strong overall commitment to protecting the innovation and commercial opportunity of our product portfolio.”

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 48, Status: Authorised

Retrieved on: 
Monday, January 8, 2024

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 48, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 48, Status: Authorised

Seizures Identified as Potential Cause of Sudden Unexplained Death in Children

Retrieved on: 
Thursday, January 4, 2024

Most are infants in what is referred to as sudden infant death syndrome, or SIDS, but 400 or more cases involve children aged 1 and older, and in what is called sudden unexplained death in children (SUDC).

Key Points: 
  • Most are infants in what is referred to as sudden infant death syndrome, or SIDS, but 400 or more cases involve children aged 1 and older, and in what is called sudden unexplained death in children (SUDC).
  • These seizures lasted less than 60 seconds and occurred within 30 minutes immediately prior to each child's death, say the study authors.
  • For decades, researchers have sought an explanation to sudden death events in children, noticing a link between those with a history of febrile seizures (seizures accompanied by fever).
  • Further research, Devinsky notes, is also needed to determine precisely how seizures with or without fever may induce sudden death.

Ukraine recap: Zelensky's defiant new year speech foreshadows tough 2024 as government tightens conscription laws

Retrieved on: 
Thursday, January 4, 2024

Ukraine advances, Ukraine overcomes the path.

Key Points: 
  • Ukraine advances, Ukraine overcomes the path.
  • He said: “Ukrainians will cope with any energy shortage as they have no shortage of resilience and courage.
  • We defeated the darkness.” He took time to thank the Ukrainian people, talking up the country’s unity in the face of existential threat.
  • A refugee or a citizen?” The cold hard fact is that 2023 ended badly on the battlefield for Ukraine.
  • As late as the beginning of December Russia announced it was calling up another 170,000 troops.
  • In the meantime, a raft of new economic measures will increase the tax burden on ordinary Ukrainians, while at the same time radically reducing public spending.
  • Read more:
    Ukraine war increasingly seen as 'fought by the poor’, as Zelensky raises taxes and proposes strict mobilisation laws
  • You can also subscribe to our fortnightly recap of expert analysis of the conflict in Ukraine.
  • James Horncastle, of Simon Fraser University in British Columbia, meanwhile, believes that while Ukraine has suffered setbacks over the past six months or so, it can still prevail.
  • And then works out exactly what it will take in terms of western military aid to achieve that initial goal.

Do they know it’s Christmas?

  • Accordingly Ukrainians celebrated Easter and other important religious festivals and saints days at different times as well.
  • But in May 2023, the Ukrainian government took the decision to adopt the revised Julian – what we know as the Gregorian – calendar.
  • As Hann reports, the old religious calendar survived the Soviet era, but has now been swept away by decree from Kyiv.

Ukraine war increasingly seen as 'fought by the poor’, as Zelensky raises taxes and proposes strict mobilisation laws

Retrieved on: 
Thursday, January 4, 2024

The demand late last year by the Ukrainian president, Volodymyr Zelensky, for the mobilisation of an additional 500,000 troops over the next few months signals both resolve and desperation.

Key Points: 
  • The demand late last year by the Ukrainian president, Volodymyr Zelensky, for the mobilisation of an additional 500,000 troops over the next few months signals both resolve and desperation.
  • It will likely make Ukrainian domestic politics more fractious but it could also buy Zelensky time to reconsider his own endgame and how to get there.
  • Against this background, the target of an additional half a million troops constitutes a significant increase of 50% above the current baseline.
  • Russia’s recent mobilisation of 170,000 new troops brings the total strength of its armed forces to around 1.3 million.

Running out of men to mobilise?

  • So the government proposes coercive measures to ensure continuing enlistment.
  • The latter group in particular, including an estimated 600,000 fighting-age men living in the EU, will become a key target of Kyiv’s mobilisation efforts.

Deepening social divisions

  • But taken together, these actions by the government have revived potentially divisive discussions in Ukrainian society about social justice, corruption and the social contract between elites and society.
  • Life expectancy of men has reduced from an already low 65 years in 2021 to 57 years in 2023.
  • Forced mobilisation, the reduction of the rights and freedoms of the population, further economic disruption and social hardship contrast sharply with what is widely perceived as the corruption-fuelled lifestyle of an entrenched and unaccountable elite.
  • Thus, Ukraine needs a new social contract between elites and society as much as it needs a re-assessment of its military strategy.
  • He is a Trustee and Honorary Treasurer of the Political Studies Association of the UK and a Senior Research Fellow at the Foreign Policy Centre in London.
  • Tetyana Malyarenko does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®

Retrieved on: 
Thursday, January 4, 2024

Under the agreement, Syneos Health will provide support in all pre-launch and launch activities for ZEPIZURE®.

Key Points: 
  • Under the agreement, Syneos Health will provide support in all pre-launch and launch activities for ZEPIZURE®.
  • Syneos Health brings a strong U.S. presence and significant expertise in commercializing new therapies for Crossject.
  • “We are pleased to support Crossject on the launch of this exciting emergency treatment for epilepsy,” said Lee Taurman, Executive Vice President, Syneos One, Syneos Health.
  • We look forward to working closely with Daniel Teper and the rest of the Crossject team to optimize the launch and commercialization for this product.”

Glytec Announces Patrick F. Cua as Chief Executive Officer

Retrieved on: 
Thursday, January 4, 2024

WALTHAM, Mass., Jan. 4, 2024 /PRNewswire/ -- Glytec, the only provider of cloud-based insulin management software as a service (SaaS) solutions across the continuum of care, today announced the appointment of Patrick F. Cua as Chief Executive Officer. In his new role, Cua will prepare the company for rapid growth to meet increasing demand for Glucommander amid a surging industry focus on healthcare outcomes, cost savings, diabetes technology, and glycemic management.

Key Points: 
  • WALTHAM, Mass., Jan. 4, 2024 /PRNewswire/ -- Glytec , the only provider of cloud-based insulin management software as a service (SaaS) solutions across the continuum of care, today announced the appointment of Patrick F. Cua as Chief Executive Officer.
  • "Glytec is an early innovator for inpatient glycemic management SaaS and has built and maintained a reputation as the trusted partner for healthcare providers," said Cua.
  • I'm excited to grow the organization and scale its technology through this transformative time, not just for Glytec, but also for healthcare and the diabetes technology industry."
  • To learn more about Glytec and its insulin management software, visit https://glytecsystems.com/ .

RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient

Retrieved on: 
Thursday, January 4, 2024

Cortical brain tissue surgically resected from the patient exhibited epileptiform bursting with microelectrode recordings.

Key Points: 
  • Cortical brain tissue surgically resected from the patient exhibited epileptiform bursting with microelectrode recordings.
  • When KRM–II–81, one of our lead GABAkines, was added the incubation fluid, the epileptiform activity in the excised brain tissue was fully suppressed.
  • Although our research team has observed suppression of activity previously in cortical tissue from epileptic patients, we have now observed recurrent epileptiform bursting in this patient’s tissue.
  • KRM-II-81 fully suppressed the epileptiform bursting, which returned when KRM-II-81 was removed from the incubation medium.